The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
about
Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitroThree-dimensional pharmacology, a subject ranging from ignorance to overstatements.Effects of antileukotrienes in the treatment of asthma.Biochemical mechanisms of drug action: what does it take for success?The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonist.Leukotrienes and inflammatory lung disease.Pharmacology of peptide leukotriene receptor antagonists.Inhibition of leukotriene biosynthesis.Initial results with oral administration of ICI 204,219.Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.Regulation of leukotriene biosynthesis.Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.The effects of a novel sulphidopeptide leukotriene antagonist, BAY x7195, against elicited bronchoconstriction in the anaesthetized guinea-pig.Comparison of Glucocorticoid (Budesonide) and Antileukotriene (Montelukast) Effect in Patients with Bronchial Asthma Determined with Body Plethysmography.Effects of KP-496, a novel dual antagonist at the cysteinyl leukotriene receptor 1 and the thromboxane A(2) receptor, on airway obstruction in guinea pigs.The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma.Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.Pharmacology of leukotriene receptor antagonistsZafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.Identification of some novel xanthine-based derivatives with bronchodilator activity.Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICI 204,219 (Accolate).MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.Asthma and anaphylaxis: a relevant model for chronic disease? An historical analysis of directions in asthma research.
P2860
Q28379600-0CD7C2E5-AC5A-4903-A004-0456053C2BC9Q31027709-11814F1F-410D-4099-90C2-868CF53D3F7DQ33836725-0EFCCC5E-449E-4162-93BC-6595948E0E93Q34344862-D5E0E493-75CC-4B73-9BC5-9BA5E0B49750Q36440015-D44BF90F-85D8-4133-B0FB-3BFEDB4306C7Q37518949-58513E62-372E-40AE-BC95-450BE4678195Q37518954-E7A951B3-2A7B-4D29-958C-31D1CD9DF1C6Q37518967-92658C5C-1C6B-49A2-98C5-659C7B5B3688Q37518972-A2029B33-5417-4728-9430-26D872B24E1DQ39710240-AF031D79-46E5-4F26-BB34-81642CD9B544Q40504270-9E1DB51F-1230-4DD2-9C2A-4995EF550C80Q40548720-572C8806-B419-455D-A926-43D1BDF535BEQ41984463-16778B25-6412-40C8-83C3-3790609AEB5BQ42125056-AFAE439F-17B0-4F74-943F-3796E8B17C1FQ42275226-08E52D53-BA3F-4CD9-BA4B-1094E6CBA77DQ42288897-AC3457F8-FCDD-47EC-A5E9-05B171578EB2Q42288898-3509327A-C171-4662-A6B5-12AAE9AF1D70Q42541812-835F921D-59AD-418A-B8A8-4EDE83BEE399Q43505948-A361F733-5556-4F2A-A2A2-87D4C9BC0870Q46362500-2FD00352-35B2-4013-B5DE-0A8D722700DEQ46879504-E9791EAC-C90E-4DD2-B48B-BD2B8E1D6CEAQ49122118-68DBDA75-BB94-47A3-B9FF-3C0BA409E189Q53652556-2946F52E-32CF-4DC3-8DF0-F5F61985E502
P2860
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@en
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@nl
type
label
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@en
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@nl
prefLabel
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@en
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@nl
P2093
P2860
P356
P1476
The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist.
@en
P2093
C K Buckner
D W Snyder
E J Kusner
P R Bernstein
V G Matassa
P2860
P304
P356
10.1164/AJRCCM/141.4_PT_1.978
P433
P577
1990-04-01T00:00:00Z